A population pharmacokinetic/pharmacodynamic analysis of regadenoson, an adenosine A2A-receptor agonist, in healthy male volunteers

Clinical Pharmacokinetics

Volumn 45, Issue 12, 2006, Pages 1201-1212

  Gordi, Toufigh ^a   Frohna, Paul ^a   Sun, Hai Ling ^b   Wolff, Andrew ^b   Belardinelli, Luiz ^a   Lieu, Hsiao ^a  

^a CV THERAPEUTICS INC   (United States)

^b Cytokinetics Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; REGADENOSON;

ADULT; ANGINA PECTORIS; ARTICLE; BLOOD ANALYSIS; BLOOD PRESSURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIZZINESS; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE INCREASE; DRUG ELIMINATION; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; DRUG URINE LEVEL; DYSPNEA; FLUSHING; HEADACHE; HEART PALPITATION; HEART RATE; HUMAN; HUMAN EXPERIMENT; MALE; NAUSEA; NORMAL HUMAN; PARAMETER; PHARMACODYNAMICS; PHASE 1 CLINICAL TRIAL; POPULATION RESEARCH; PRIORITY JOURNAL; QT DISPERSION; QT INTERVAL; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SINGLE DRUG DOSE; ST SEGMENT DEPRESSION; STANDING; SUPINE POSITION; SYNCOPE; T WAVE INVERSION; THORAX PAIN; URINALYSIS; VASODILATATION; VOMITING;

ADULT; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; HEADACHE; HEART RATE; HUMANS; INJECTIONS, INTRAVENOUS; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; MODELS, BIOLOGICAL; NAUSEA; PURINES; PYRAZOLES; RECEPTOR, ADENOSINE A2A; VASODILATOR AGENTS; VOMITING;

EID: 33845445489     PISSN: 03125963     EISSN: 03125963     Source Type: Journal    
DOI: 10.2165/00003088-200645120-00005     Document Type: Article

References (12)

1. Ranhosky A, Kempthorne-Rawson J. The safety of intravenous dipyridamole thallium myocardial perfusion imaging. Intravenous Dipyridamole Thallium Imaging Study Group. Circulation 1990; 81 (4): 1205-9
2. Cerqueira MD, Verani MS, Schwaiger M, et al. Safety profile of adenosine stress perfusion imaging: results from the Adenoscan Multicenter Trial Registry. J Am Coll Cardiol 1994; 23 (2): 384-9
3. Trochu JN, Zhao G, Post H, et al. Selective A2A adenosine receptor agonist as a coronary vasodilator in conscious dogs: potential for use in myocardial perfusion imaging. J Cardiovasc Pharmacol 2003; 41 (1): 132-9
4. Zhao G, Linke A, Xu X, et al. Comparative profile of vasodilation by CVT-3146, a novel A2A receptor agonist, and adenosine in conscious dogs. J Pharmacol Exp Ther 2003; 307 (1): 182-9
5. Ellenbogen KA, O'Neill G, Prystowsky EN, et al. Trial to evaluate the management of paroxysmal supraventricular tachycardia during an electrophysiology study with tecadenoson. Circulation 2005; 111 (24): 3202-8
6. Meade CJ, Dumont I, Worrall L. Why do asthmatic subjects respond so strongly to inhaled adenosine? Life Sci 2001; 69 (11): 1225-40
7. Jonsson EN, Karlsson MO. Xpose- an S-PLUS based population Therapharmacokinetic/pharmacodynamic model building aid for NONMEM. Comput Methods Programs Biomed 1999; 58: 51-64
8. Holford N. The visual predictive check: superiority to standard diagnostic (Rorschach) plots [abstract No. 738]. 14th annual meeting of PAGE (Population Approach Group Europe); 2005 Jun 16-17; Pamplona
9. Jusko WJ, Levy G. Pharmacokinetic evidence for saturable renal tubular reabsorption of riboflavin. J Pharm Sci 1970; 59: 765-72
10. Shryock JC, Snowdy S, Baraldi PG, et al. A2A-adenosine receptor reserve for coronary vasodilation. Circulation 1998; 98 (7): 711-8
11. Engelstein ED, Lerman BB, Somers VK, et al. Role of arterial chemoreceptors in mediating the effects of endogenous adenosine on sympathetic nerve activity. Circulation 1994; 90 (6): 2919-26
12. Dhalla AK, Wong MY, Wang WQ, et al. Tachycardia caused by A2A adenosine receptor agonists is mediated by direct sympathoexcitation in awake rats. J Pharmacol Exp Ther 2006 Feb; 316 (2): 695-702